Patient survey - Autosomal dominant polycystic kidney disease (ADPKD) - Institut national d'excellence en santé et en services sociaux (INESSS)
Patient survey - ADPKD - INESSS
The Kidney Foundation of Canada would like to thank you for your participation in this short survey. The estimated time to complete it is approximately 5 minutes. The survey will be conducted confidentially and will respect the anonymity of respondents.
The goal behind this survey is to better understand your reality as a patient living with polycystic kidney disease (PKD) and more precisely autosomal dominant polycystic kidney disease (ADPKD). The survey concentrates on three areas;
The impact ADPKD has on patient quality of life
The extent to which ADPKD patients, with the help of their families cope with the condition including experience with current therapies
The experience that ADPKD patients who are eligible to receive Tolvaptan have had with the medication
The objective of this survey is to demonstrate that patients living with ADPKD in Quebec, may benefit from better access to other treatment options.
The data collected will be submitted to the INESSS (Institut national d’excellence en santé et en services sociaux), the provincial entity responsible for evaluating for public funding medications in Quebec.
Thank you for your time and collaboration on this initiative.
_________________________________ *Kindly note that the remainder of the survey will focus on autosomal dominant polycystic kidney disease and will be referred to as ’ADPKD’.